Clinical Research Directory

Inclusion Criteria: * Histologically confirmed cancer, Stage I-IV, in one of the following: Cervical, rectal, nodal Non-Hodgkin lymphoma, cutaneous lymphoma, Head \& neck cancer * Diagnostic/pre-treatment biopsy confirmed suitable for translational research \* * Performance status - ECOG 0-2 (Refer to appendix 1), ECOG 3 allowed for arm F (unrelated to underlying cancer) as this group of patients often have ECOG 3 due to age and comorbidities. * Age ≥ 18; no upper age limit. * Participant considered suitable for radiotherapy * Before participant registration, written informed consent must be given according to GCP and national regulations. \*Pre-treatment biopsy must be from the gross tumour volume within the planned radiation field and must also: * Have been formalin fixed for \>12h and \<72h * Have tumour tissue and morphology confirmed by H\&E staining * Contain sufficient tumour cells (approximately 100) Exclusion Criteria: * Participants deemed unsuitable for a biopsy (during or following radiotherapy) in the opinion of the treating oncologist. * Participants who have received chemotherapy within 28 days of starting radiotherapy. * Participants with intercurrent or past history of hepatitis B, C or human immunodeficiency virus infection if known. A negative test result for hepatitis B, C and HIV infection is required prior to inclusion in the study.